2010
News
June 4, 2010: Haberman Associates’
Biopharmconsortium Blog, formerly at http://biopharmconsortium.blogspot.com, has
moved to our own site. You can now find it at http://biopharmconsortium.com/blog.
We
started the Biopharmconsortium Blog in July of 2009. The blog contains expert
commentary on recent life science industry news and recent published scientific
reports and business articles.
We hope that
you will continue to visit and subscribe to our blog in its new location. We also
welcome comments and discussions of our blog articles from people in the life
science community, including companies, academic institutions, and disease organizations
and patient advocates.
March 16, 2010:
“Reducing
Attrition In Silico” by Allan B. Haberman, Ph.D. was published in the
March-April 2010 issue of Bio-IT World. This article is based on an excerpt
from Chapter 8 of the recently published book-length report Animal Models for
Therapeutic Strategies.
March 5, 2010:
Cambridge Healthtech Institute (CHI) announced the publication of a new book-length
report, Animal Models for Therapeutic Strategies, by Allan B.
Haberman, Ph.D. This new Insight Pharma Report discusses the use of animal
models to develop new paradigms for drug discovery and development in important
human diseases. The report also discusses strategies for developing more predictive
models of drug efficacy. Poorly predictive animal models are a major reason for
Phase II and Phase III pipeline drug attrition. Thus this new report complements
our May 2009 Insight Pharma Report, Approaches
to Reducing Phase II Attrition.
For more information on the
report, or to order it, see the CHI
Insight Pharma Reports website.
2009
News
September 11, 2009: Haberman
Associates joined Innovalyst
as an Affiliate.
Innovalyst is a North Carolina-based
consulting consortium. It is led by four Managing Partners with over 20 years
of industrial experience as executives at top-tier pharmaceutical or biotechnology
companies. Innovalyst's Intellectual Capital Advisory Network (ICAN) also includes
over 75 Affiliates with an extraordinary breadth and depth of life science business
skills.
Since 1997, Haberman Associates has
been a member of the Biopharmaceutical Consortium (BPC), a Boston-based life science
consulting network. We shall continue to maintain our membership in BPC, and our
Boston-area location. However, we shall also expand our network to include Innovalyst.
In addition to Haberman Associates, another BPC member, Trilogy Associates (headed
by Joseph Kalinowski), is both a member of BPC and an Innovalyst Affiliate. Trilogy
relocated to North Carolina in 2008.
Haberman
Associates will maintain its primary focus on science and technology strategy,
and on new product development via internal R&D and partnering. However, we
shall be able to draw on our partners in BPC and Innovalyst to form project teams
to take on larger, more complex projects requiring multiple areas of expertise,
especially for large pharmaceutical and biotechnology companies. We shall also
continue to serve life science clients of all sizes, from start-ups to major corporations.
If
you have any questions about Haberman Associates and its expanded consulting network,
or would like to discuss your company's needs, please contact
us.
September 11, 2009: Allan B.
Haberman, Ph.D. was quoted in an article entitled "Bristol-Myers Squibb swallows
last of antibody pioneers", by Malorye Allison, in the September issue of
Nature Biotechnology. The article focused on the monoclonal antibody sector,
especially on the recent acquisition of Medarex by Bristol-Myers Squibb.
To
read the article, go to www.nature.com/nbt/journal/v27/n9/full/nbt0909-781.html
(subscription required).
August 3,
2009: Genetic Engineering
and Biotechnology News
featured an article by Allan B. Haberman, Ph.D.
on Page One of its August 2009 edition. The article, entitled "Overcoming
Phase II Attrition Problem", is based in part on our recent book-length
report, Approaches
to Reducing Phase II Attrition, published by Cambridge Healthtech Institute
(CHI).
July 13, 2009. Haberman
Associates has created a new blog, the Biopharmconsortium Blog, located at:
http://biopharmconsortium.blogspot.com.
Our
blog is intended to be your place on the Web for discussion of scientific and
business issues in the biotechnology, pharmaceutical, diagnostics, and research
products industry. People in the industry and in the wider biomedical research
community are invited to visit the blog, and to subscribe to and comment on its
posts.
May 5, 2009: Cambridge
Healthtech Institute (CHI) announced the publication of a new book-length report,
Approaches to Reducing Phase II Attrition, by Allan B. Haberman, Ph.D.
This new Insight Pharma Report discusses leading-edge strategies to improve R&D
productivity in the pharmaceutical and biotechnology industry, which is arguably
the central challenge in the industry today. These strategies, which focus on
translational medicine, are aimed at lowering R&D costs and enabling the industry
to successfully develop innovative drugs that address unmet medical needs. The
report also includes an analysis of the results of an industry survey on strategies
to improve R&D productivity, and complete transcripts of expert interviews.
For
more information on the report, or to order it, see the CHI
Insight Pharma Reports website.
February
1, 2009: Genetic Engineering
News published an article by Allan B. Haberman, Ph.D. in its February
1, 2009 edition, entitled "Strategies
to Overcome Blood-Brain Barrier" This article is based in part on our
recent book-length report, Blood-Brain
Barrier: Bridging Options for Drug Discovery and Development, published
by Cambridge Healthtech Institute (CHI).
January
22, 2009: Allan B. Haberman, Ph.D. gave a presentation, entitled "The
Therapeutic RNAi Market - Lessons from the Evolution of the Biologics Market"
at the conference "Executing on the Promise of RNAi", Cambridge MA,
January 22-23, 2009.
